Drug Profile
DHES 0815A
Alternative Names: DHES-0815A; RG 6148Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HER2 positive breast cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion)
- 28 Feb 2022 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 11 Dec 2021 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in HER2-positive-breast-cancer presented at the 44th Annual San Antonio Breast Cancer Symposium (SABCS-2021)